Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Holdings Lessened by Deutsche Bank AG

Deutsche Bank AG cut its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Free Report) by 33.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,236,639 shares of the company's stock after selling 629,496 shares during the quarter. Deutsche Bank AG owned approximately 0.49% of Maravai LifeSciences worth $6,740,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in MRVI. Franklin Resources Inc. acquired a new position in Maravai LifeSciences during the 3rd quarter worth $600,000. SG Americas Securities LLC lifted its holdings in Maravai LifeSciences by 7.3% during the 4th quarter. SG Americas Securities LLC now owns 33,046 shares of the company's stock worth $180,000 after buying an additional 2,239 shares during the last quarter. Patriot Financial Group Insurance Agency LLC bought a new stake in shares of Maravai LifeSciences in the 4th quarter valued at approximately $136,000. China Universal Asset Management Co. Ltd. raised its position in shares of Maravai LifeSciences by 10.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 30,076 shares of the company's stock valued at $164,000 after acquiring an additional 2,851 shares in the last quarter. Finally, Jennison Associates LLC lifted its stake in Maravai LifeSciences by 0.3% during the fourth quarter. Jennison Associates LLC now owns 2,990,414 shares of the company's stock worth $16,298,000 after purchasing an additional 9,769 shares during the last quarter. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Maravai LifeSciences Price Performance

Shares of MRVI stock traded down $0.15 during midday trading on Wednesday, reaching $2.25. 2,428,954 shares of the company were exchanged, compared to its average volume of 2,347,378. The company's 50 day moving average price is $2.09 and its two-hundred day moving average price is $3.96. The company has a market cap of $572.99 million, a P/E ratio of -1.37 and a beta of 0.19. Maravai LifeSciences Holdings, Inc. has a 12 month low of $1.67 and a 12 month high of $11.50. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The firm had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences had a negative return on equity of 6.61% and a negative net margin of 81.13%. Maravai LifeSciences's revenue for the quarter was down 26.9% compared to the same quarter last year. On average, sell-side analysts expect that Maravai LifeSciences Holdings, Inc. will post -0.24 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. UBS Group lowered their price objective on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating for the company in a research report on Friday, March 21st. Robert W. Baird dropped their price target on Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Stifel Nicolaus set a $5.00 price objective on Maravai LifeSciences in a research report on Friday, March 21st. Craig Hallum dropped their target price on Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Finally, Morgan Stanley dropped their price objective on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average target price of $6.64.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.